ClinicalTrials.gg
RecruitingNCT04366804Updated Apr 13, 2025

International Validation of Two Non-motor Scales in PD (NFS and SPARK)

An observational study in Parkinson's Disease and Non-motor Symptoms, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 8 sites in 7 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 7 under way, none of them phase 3. Parkinson Disease · Insel Gruppe AG, University Hospital Bern.

Started
2020
the only one that year
Observational
3 of 10
1 open now
Registered
2nd of 10
by date

Among the 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern, this one is the only one that started in 2020, is one of 3 observational ones, and was the 2nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Parkinson Disease by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

The goal of this project is to develop the international validation of two new rating scales, the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale, in order to improve the understanding of the extent and severity of non-motor symptoms in Parkinson's disease (PD).

Read the detailed description

This project is a prospective international multicentre study to validate two new rating scales in different languages: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale.

The project population consists a minimum of 300 PD patients with and without fluctuations in the participant countries: Spain, Germany, France, Switzerland, Romania and Greece.

The NFS is specifically designed to detect neuropsychiatric fluctuations between off- and on-medication condition in PD. It is composed of 20 items, 10 items measuring the on-neuropsychological symptoms and 10 items for the off-neuropsychological manifestations. The validation of this scale, based on the most frequently experienced symptoms by the patients, would allow a crucial breakthrough in the improvement of management of PD patients.

Shame and embarrassment are poorly recognized by physicians in PD. PD-related shame and embarrassment may emerge from motor and non-motor symptoms, from self-perception of inadequacy due to loss of autonomy and need for help, or from perceived deterioration of body image. The current available scales are not specific for PD. Based on reports of persons affected with PD and a literature review about shame and stigmatization in PD a 25-items self-questionnaire for shame and embarrassment in PD was created. The scale includes 6 different subscales (1. Shame arising from PD symptoms; 2. Shame arising from the increasing physical dependence and need for help induced by PD; 3. Shame arising from the patient's assumption of breaking certain social rules; 4. Shame arising from the deteriorated body image; 5. Consequence of related shame and embarrassment on patients' health-related quality of life; 6. Stigmatization). The validation of this scale will give a tool for physicians and researchers to better understand the impact of PD on patient's quality of life.

03

Conditions studied

  • Parkinson's Disease
  • Non-motor Symptoms

Browse trials for

Keywords

  • Parkinson's Disease
  • Non-motor symptoms
  • Scales for non-motor symptoms
  • Validation
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The project population consists of PD patients with and without neuropsychiatric fluctuations attending routine visits to movement disorders clinics in the participant countries. Only patients capable of giving informed consent will be considered for participation in this project.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written ;
  2. PD, according to the MDS criteria;
  3. Age of participants > 30 and \< 75 years;
  4. Being fluent in the language in which the scales are applied.

Exclusion criteria

Exclusion Criteria:

  1. Presence of PD dementia (defined as score \< 24).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with neuropsychiatric fluctuations

    PD patients with neuropsychiatric fluctuations (≥ 2 positive answers in QUICK test)

  • Patients without neuropsychiatric fluctuations

    PD patients without neuropsychiatric fluctuations (≤ 1 positive answer in QUICK test)

06

What researchers measure

Primary outcomes

  1. NFS score

    Time frame: 2 weeks (2 assessments in a time span of 2 weeks)

  2. SPARK score

    Time frame: 2 weeks (2 assessments in a time span of 2 weeks)

07

Study locations

2 of 8 sites recruiting
  • Centre hospitalier régional universitaire de Besançon
    Besançon, 25000, France
    Completed

    Not enrolling at this site.

  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
    Completed

    Not enrolling at this site.

  • Aristotle University of Thessaloniki
    Thessaloniki, 541 24, Greece
    Completed

    Not enrolling at this site.

  • Transilvania University
    Brasov, 500036, Romania
    Recruiting
  • Hospital Universitario Burgos
    Burgos, 09006, Spain
    Completed

    Not enrolling at this site.

  • Ruber International Hospital
    Madrid, 28034, Spain
    Completed

    Not enrolling at this site.

  • Insel Gruppe AG University Hospital Bern
    Bern, 3010, Switzerland
    Completed

    Not enrolling at this site.

  • King's College London
    London, WC2R 2LS, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Sep 2025, 57 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 57 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2020
First posted
Apr 29, 2020
StartActual
Dec 3, 2020
Primary completionEst.
Sep 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04366804
Collaborators
Michael J. Fox Foundation for Parkinson's Research, Carlos III Health Institute
Responsible party
Sponsor
First posted
Apr 29, 2020
Start date
Dec 3, 2020
Primary completion
Sep 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 13, 2025

Study contacts

Ines Debove, MD
Contact
ines.debove@insel.ch
+41 31 63 2 79 24
Paul Krack, MD, PhD
principal investigator · Insel Gruppe AG, University Hospital Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion